· Circio will present new and strengthened circVec in vivo proof-of-concept data
at the American Society of Gene and Cell Therapy (ASGCT) annual meeting
  · The poster presentation will take place on 13 May 2025 in New Orleans, USA
  · ASGCT is considered the most prestigious and widely attended international
conference in the gene and cell therapy field

Oslo, Norway 6 May 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, today announces that it will present new and strengthened circVec
circular RNA in vivo data at the American Society of Gene and Cell Therapy
(ASGCT) annual meeting 2025 taking place in New Orleans, USA, 13-17 May 2025.

In the poster presentation, Circio will showcase the latest in vivo results for
the circVec synthetic DNA and AAV gene therapy platform. circVec circular RNA
-based vectors have the potential to substantially boost protein expression
level and durability for both viral and non-viral gene and cell therapy.
Recently generated in vivo data further validates and strengthens the circVec
system in specific settings, and provides important context to prioritize
development areas and partnering strategy.

Title of presentation:
CircVec: a powerful circular RNA expression platform to enhance viral and non
-viral gene and cell therapies

Time and poster number:
13 May 2025, 18:00-19:30hrs CDT, poster #655

Location:
Ernest N. Morial Convention Center, New Orleans, Louisiana, USA

The poster will be made available on CircioŽs webpage (http://www.circio.com/)
after the presentation